Dysmenorrhea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Dysmenorrhea Marketed and Pipeline Drugs Report Overview

Dysmenorrhea (DM) is uterine pain, which may occur with menses or precede menses by one to three days. It is often crampy or a dull constant ache but may be sharp or throbbing, which may radiate to the back or legs. DM is sometimes accompanied by symptoms of premenstrual syndrome (PMS) or heavy menstrual bleeding and passage of blood clots.

The dysmenorrhea marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for dysmenorrhea.

The report also provides actionable insights into the clinical and commercial landscapes of AH, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.

Dysmenorrhea Marketed Drugs Segmentation by Mechanisms of Action

Most of the marketed drugs for DM are enzyme inhibitors in 2024. They are followed by receptor antagonists, receptor agonists, ion channel activator, enzyme activator, and others.

Dysmenorrhea Marketed Drugs Analysis by Mechanisms of Action, 2024 (%)

Buy the Full Report to Know More about the MoA of Dysmenorrhea Marketed Drugs

Download a Free Report Sample

Dysmenorrhea Marketed Drugs Segmentation by Molecule Types

In 2024, the leading molecule type for dysmenorrhea marketed drugs is biologics, followed by small molecule.

Dysmenorrhea Marketed Drugs Analysis by Molecule Types, 2024 (%)

Buy the Full Report to Know More about the Molecule Types of Dysmenorrhea Marketed Drugs

Download a Free Report Sample

Dysmenorrhea Pipeline Drugs Market Segmentation by Mechanisms of Action

The key MoA of the drugs in the dysmenorrhea pipeline includes enzyme inhibitors and receptor agonists. The DM pipeline mainly includes molecules that are enzyme inhibitors in 2024.

Dysmenorrhea Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)

Buy the Full Report to Know More about the MoA of Dysmenorrhea Pipeline Drugs

Download a Free Report Sample

Dysmenorrhea Pipeline Drugs Market Segmentation by Routes of Administration

In 2024, the DM pipeline mainly includes molecules that are administered orally. The suppository is another route by which pipeline drugs are administered as well.

Dysmenorrhea Pipeline Drugs Market Analysis by Routes of Administration, 2024 (%)

Buy the Full Report to Know More about the Routes of Administration of Dysmenorrhea Pipeline Drugs, Download a Free Report Sample

Dysmenorrhea Marketed and Pipeline Drugs Market – Competitive Landscape

A few of the top sponsors in the dysmenorrhea marketed and pipeline drugs market are Shahid Beheshti University of Medical Sciences, Mashhad University of Medical Sciences, International Bio Service Co Ltd, Tabriz University of Medical Sciences, Bayer AG, and others. Shahid Beheshti University of Medical Sciences is sponsoring the highest number of trials in 2024.

Dysmenorrhea Marketed and Pipeline Drugs Market Analysis by Sponsors, 2024 (%)

Buy the Full Report for More Sponsor Insights into the Dysmenorrhea Marketed and Pipeline Drugs Market, Download a Free Report Sample

Segments Covered in the Report

Dysmenorrhea Marketed Drugs Mechanisms of Action Outlook (2024)

• Enzyme Inhibitors
• Receptor Antagonists
• Receptor Agonists
• Ion Channel Activator
• Enzyme Activator

Dysmenorrhea Marketed Drugs Molecule Types Outlook (2024)

• Small Molecules
• Biologics

Dysmenorrhea Pipeline Drugs Mechanisms of Action Outlook (2024)

• Receptor Antagonists
• Enzyme Inhibitors

Dysmenorrhea Pipeline Drugs Routes of Administration Outlook (2024)

• Oral
• Suppository

Scope

The key components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the dysmenorrhea market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global dysmenorrhea market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.